Concentrations of prostaglandins E2 and I2 may be decreased in preeclamptic and eclamptic pregnancies. Because these prostaglandins produce vasodilation and inhibit platelet aggregation it has been suggested that a reduction in their biosynthesis might play an important role in the pathogenesis of the hypertension and coagulation abnormalities associated with preeclampsia. Placental tissue is an extremely rich source of several enzymes that catalyze the catabolism of prostaglandins. The present study was initiated to determine whether one of these catabolic enzymes might be increased in preeclamptic/ eclamptic pregnancies. The activities of the NAD-and the NADP-linked 15-hydroxyprostaglandin dehydrogenases were measured in 16 preeclamptics (mean diastolic pressure, 108±13 mmHg) and compared with 16 normotensive controls matched for age (20.8±5.43 vs. 20.6±5.16) and gestational week of delivery (34.6±5.40 vs. 35.0±5.06). These results indicate that the activity of the placental NAD-linked 15-hydroxyprostaglandin dehydrogenase is elevated in preeclampsia (40.1±31.3 vs. 14.9±8.30 mU/g tissue, P < 0.01). If this increase were also expressed in vivo, its effect on prostaglandin metabolism could be mistaken for impaired prostacyclin biosynthesis unless both the 6-keto-and 6,15-diketo-metabolites of prostacyclin were measured.
Introduction
Preeclampsia, a hypertensive disorder peculiar to pregnancy, is accompanied by proteinuria and edema. It may be associated with coagulation abnormalities including increased platelet aggregation. In addition, all of the components of the reninangiotensin-aldosterone system are decreased (1, 2) . Because of the relationship between prostaglandins and the renin-angiotensin system, Speroff(3) proposed that the development of preeclampsia could represent defective prostaglandin production.
Subsequently a large body of work has suggested that this may, in fact, be so. Initially investigators focused on the possible role of prostaglandins of the E series. Alam et al. (4) Receivedfor publication 11 February 1987 and in revisedform 18 May 1987. onstrated a decreased ability of the placenta to metabolize prostaglandin El (PGE,)' in individuals with preeclampsia, whereas others (5, 6) found decreased concentrations of these prostaglandins in the placenta, amnion, chorion, and decidua of preeclamptic subjects.
More recently attention has shifted to PGI2 (7) , an agent that is more effective than PGE2 in causing vasodilation and inhibiting platelet aggregation. Because PGI2 is quite labile, its concentration is measured indirectly, either by determining the concentration of 6-keto PGFIa (its stable hydration product) or by bioassay (inhibition of platelet aggregation). Using these methods, decreased "prostacyclin" concentrations have been found in umbilical and placental vasculature (8-13), maternal and umbilical plasma (13) , and placental homogenates (14) of preeclamptic subjects. The discovery that thromboxane A2 (TXA2) has physiologic effects opposite those of PG12 has led to the hypothesis that the concentration of PGI2 relative to the concentration of TXA2 is lower in preeclamptic than in normal pregnancies (15) (16) (17) (18) . This hypothesis has received some indirect support from studies that have sought to increase the ratio of PG12 to TXA2 by PGI2 infusion (19) (20) (21) or preferential inhibition (22, 23) of TXA2 synthesis by aspirin (16) or by other nonsteroidal antiinflammatory agents (23) . In both a retrospective study (24) and randomized, double-blind trial (16) , investigators observed that pregnant individuals who took aspirin developed hypertension and proteinuria less frequently than those who did not.
The concentration of endogeneous substances depends not only on the rate of their biosynthesis but also on the rates of their catabolism and clearance. Because the placenta has a much greater capacity to degrade prostaglandins than to synthesize them (25, 26) , we chose to evaluate the possibility that the placental catabolism of prostaglandins is greater in preeclamptic than in normal subjects.
To do this, we measured the activity of two placental enzymes in preeclamptic and normotensive pregnancies. These enzymes, the NAD-linked (EC 1.1.1.141) and NADP-linked 15-hydroxyprostaglandin dehydrogenases, catalyze the first step in prostaglandin catabolism, oxidation of the 15-hydroxyl group to a ketone. This oxidation results in the biologic inactivation of these compounds (27) .
Methods
16 patients with preeclampsia/eclampsia were studied. The same number of normotensive women with gestational ages comparable with the preeclamptic subjects served as controls. With one exception in each group, all were nulliparous. None had a previous history of hypertension, renal disease, or diabetes mellitus. The patients were selected on the basis of having a normal blood pressure before pregnancy and developing a sustained blood pressure during pregnancy . 140/90 mmHg or having a sustained systolic (2 30 mmHg) and diastolic (. 15 mmHg) rise in pressure. In addition, all subjects displayed proteinuria whereas 14 had edema of the hands and/or face, and two convulsed. All received Mg2SO4 and 11 were also treated with hydralazine.
All of the placentas were examined grossly, and appropriate sections (containing < 10 g of tissue) were examined microscopically in the Pathology Laboratory at Chicago Lying-In Hospital. None of the preterm deliveries were due to local infection, fetal death, or disorders that might involve prostaglandins (e.g., hydramnios).
Enzyme assays. Each placenta was chilled immediately after delivery. Within 4 h of delivery, the villous tissue was thoroughly rinsed in cold tap water, separated from its membranes, and homogenized in 75-g batches at top speed for 2 min in a Waring blender. Each batch was homogenized in 150 ml of buffer containing 5 mM potassium phosphate, pH 7.0, and 1 mM EDTA. The homogenates were centrifuged at 10,000 g for I h. Both the homogenization and the centrifugation were conducted at 0-40C. The supernatant solution was assayed for the NAD-and the NADP-linked hydroxyprostaglandin dehydrogenase activities. The NAD-linked enzyme was assayed as follows: the reaction cuvet (1.0-cm light path) contained, in a volume of 3.0 ml, 290 gmol ofpotassium phosphate, pH 7.0, 1,35 gmol ofNAD, and 14 nmol of PGEI in 0.02 ml of 95% ethanol. The substrate, but not ethanol, was omitted from the blank. The NADP-linked enzyme was assayed similarly except that 1.08 Mmol of NADP, and 120 nmol of PGBI were present instead of NAD and PGE1. The reactions were initiated by the addition of enzyme. They were run in duplicate at 25±0.50C in a model 240 recording spectrophotometer (Gilford Instruments Laboratories, Inc., Oberlin, OH). Initial reaction rates were determined by measuring the change in absorbance at 340 nm. 1 U of enzyme activity is defined as the amount of enzyme that catalyzes the reduction of 1 Mmol of cofactor per min under the conditions of the assay.
Prostaglandins were obtained from the Upjohn Co., Kalamazoo, MI, and pyridine nucleotides from P-L Biochemicals Inc., Milwaukee, WI.
Data are presented as mean and SEM. The two-tailed t test for unpaired data was used for comparison of the data from hypertensive and normotensive subjects.
Results
Clinical profiles of both preeclamptic/eclamptic and normotensive subjects are summarized in Table I The presence of Mg2' (10-6_10-1 M) in the assay cuvets did not increase the activity of the NAD-linked enzyme that had been isolated from normotensive individuals (data not shown). (14) . This led Walsh et al. to con- clude: "precursor availability is not a limiting factor and cannot account for the difference in prostacyclin production by normal and toxemic placentas" (14) . Kreise et al. used monoclonal antibodies to measure the uterine enzymes involved in prostacyclin synthesis (the prostacyclin synthase and the prostaglandin endoperoxide synthase) and found that the concentrations of these enzymes did not differ between subjects with severe preeclampsia and those with normal blood pressures (32) .
The findings outlined in the two preceding paragraphs raise the possibility that there are alternative or additional explanations to account for!,/the decreased PGE2 or PGI2 concentra-'tions in placentas from preeclamptic pregnancies. The results of the present study suggest such an explanation in at least 938 J. Jarabak, J. D. Watkins, and M. Lindheimer some instances: the activity of the first enzyme in the pathway ofprostaglandin catabolism, the NAD-linked 1 5-hydroxyprostaglandin dehydrogenase, is significantly higher in placentas obtained from subjects with preeclampsia/eclampsia than in those obtained from subjects who are normotensive.
Placental tissue contains an NAD-linked and an NADPlinked enzyme with 15-hydroxyprostaglandin dehydrogenase activity (25, 33) . The NAD-linked enzyme catalyzes the 15-oxidation of PGI2 as well as PGE2 (34) . A similar enzymatic oxidation of PGI2 has been demonstrated to occur in blood vessels (35) , lung (36) , and kidney (37) but it is not clear whether a single enzyme catalyzes these reactions. Extensive structure-activity studies have demonstrated that the NADlinked enzyme has a greater catalytic efficiency (k<,/Km) for prostaglandins than for other compounds, whereas the NADP-linked enzyme is a less specific carbonyl reductase (38) . In this light it is noteworthy that we have observed a significant increase in only the NAD-linked activity in placentas from preeclamptic/eclamptic pregnancies.
Kinetic studies on the NAD-linked enzyme reveal that its 6 -keto PGF1, and 6-keto-2,3-dinor PGFI,) and increased excretion of others (e.g., 6,15-diketo-13, 14-dihydro PGFIa and 6,1 5-diketo-13, 14-dihydro-2,3-dinor PGFI,). Whekeas decreased excretion of 6-keto PGF1. has been demonstrated in a) number of studies of preeclamptic pregnancies, only Goodman et al. (30) have used gas chromatography-mass spectroscopy to address the issue of whether this alteration is due solely to decreased prostacyclin biosynthesis. They measured the urinary excretion of 6-keto-2,3-dinor PGFi, and 6,1 5-diketo-13, 14-dihydro-2,3-dinor PGFia in preeclamptic and normotensive pregnancies. The excretion of both compounds was lower in preeclamptic than in normotensive pregnancies, but there was no difference in the ratio of the 6,1 5-diketo-to the 6-keto-compound when the two groups (n = 5 in both groups) were compared.
The results of the present study indicate that the activity of the placental NAD-linked 15-hydroxyprostaglandin dehydrogenase is elevated in preeclamptic pregnancies. If this in vitro increase in enzyme activity were also expressed in vivo, one consequence would be to alter the excretion of 6-keto PGFia in such a way to suggest impaired prostacyclin biosynthesis. Thus prostaglandin catabolism may have contributed to findings previously attributed solely to prostacyclin production. Although the most rigorous study of prostacyclin metabolism in preeclampsia (30) has not shown an increase in prostacyclin catabolism, the importance of this issue from an etiologic and a therapeutic standpoint and the limited number of observations specifically dealing with it suggest the need for future studies to directly assess the contribution of prostacyclin catabolism to the genesis of decreased 6-keto PGFIa in preeclampsia. This will require the measurement of both the 6-keto-and 6,15-diketo-metabolites of prostacyclin if in vivo studies are performed.
